- Home
- SIG vs TARS Comparison
SIG vs TARS Comparison
Compare SIG & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SIG | TARS |
|---|---|---|
| Founded | 1950 | 2016 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.6B |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SIG | TARS |
|---|---|---|
| Price | $117.31 | $68.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $125.90 | $99.80 |
| AVG Volume (30 Days) | ★ 694.9K | 652.8K |
| Earning Date | 12-01-2026 | 11-03-2026 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | ★ 974.07 | 48.21 |
| EPS | ★ 2.11 | N/A |
| Revenue | ★ $6,247,100,000.00 | $451,360,000.00 |
| Revenue This Year | $0.74 | $61.17 |
| Revenue Next Year | $1.97 | $26.47 |
| P/E Ratio | $55.45 | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $71.62 | $53.89 |
| 52 Week High | $122.64 | $91.53 |
Technical Indicators
Market Signals| Indicator | SIG | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 71.08 | 39.23 |
| Support Level | $80.03 | $60.95 |
| Resistance Level | $122.64 | $74.51 |
| Average True Range (ATR) | 4.02 | 3.34 |
| MACD | 0.53 | -0.37 |
| Stochastic Oscillator | 74.48 | 2.22 |
Price Performance
Historical ComparisonAbout SIG Signet Jewelers Limited
Signet Jewelers Ltd is a retailer of diamond jewelry. Its merchandise mix includes bridal, fashion, watches, and others. The bridal category includes engagement, wedding, and anniversary purchases. Its segments are the North America segment, the International segment, and the Other segment. The North America segment contributes to the majority of the revenue. The North America segment generates revenue from Mall and Outlet. Geographically, it operates in the USA, Canada, the UK, and Ireland, with the maximum revenue from the USA.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.